Ya-Wen Hung1, I-Cheng Lee1,2, Chen-Ta Chi1,2,3, Rheun-Chuan Lee4, Chien-An Liu4, Nai-Chi Chiu4, Hsuen-En Hwang4, Yee Chao5, Ming-Chih Hou1,2, Yi-Hsiang Huang1,2,3. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Faculty of Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan. 3. Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. 4. Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Abstract
BACKGROUND AND AIMS: For patients with intermediate-stage hepatocellular carcinoma (HCC), the definition of high tumor burden remains controversial. This study aimed to compare the prognostic value of different criteria of tumor burden in patients with intermediate-stage HCC undergoing transarterial chemoembolization (TACE). METHODS: From 2007 to 2019, 632 treatment-naive patients with intermediate-stage HCC undergoing TACE were retrospectively enrolled. We compared different criteria of tumor burden in discriminating radiologic response and survival, including up-to-7, up-to-11, 5-7, 7 lesions criteria, and newly proposed 7-11 criteria. RESULTS: The proportions of patients classified as high tumor burden were varied by different criteria. Among the 5 criteria, 7-11 criteria have the best performance to discriminate complete response (CR) and overall survival (OS) after TACE. In patients with low, intermediate, and high tumor burden classified by 7-11 criteria, the CR rate was 21, 12, and 2.5%, respectively (p < 0.001), and the median OS was 33.1, 22.3, and 11.9 months, respectively (p < 0.001). By multivariate analysis, 7-11 criteria were significantly associated with CR (intermediate vs. high burden, odds ratio = 4.617, p = 0.002; low vs. high burden, odds ratio = 8.675, p < 0.001) and OS (intermediate vs. high burden, hazard ratio = 0.650, p < 0.001; low vs. high burden, hazard ratio = 0.520, p < 0.001). Seven to 11 criteria also had the lowest corrected Akaike information criteria, highest homogeneity value, and highest area under the receiver operating characteristic curve in predicting 1-, 2-, and 3-year mortality among all criteria. CONCLUSION: Conventional definitions of tumor burden were not optimal for patients with intermediate HCC. The new 7-11 criteria had the best discriminative power in predicting radiologic response and survival in patients with intermediate-stage HCC undergoing TACE.
BACKGROUND AND AIMS: For patients with intermediate-stage hepatocellular carcinoma (HCC), the definition of high tumor burden remains controversial. This study aimed to compare the prognostic value of different criteria of tumor burden in patients with intermediate-stage HCC undergoing transarterial chemoembolization (TACE). METHODS: From 2007 to 2019, 632 treatment-naive patients with intermediate-stage HCC undergoing TACE were retrospectively enrolled. We compared different criteria of tumor burden in discriminating radiologic response and survival, including up-to-7, up-to-11, 5-7, 7 lesions criteria, and newly proposed 7-11 criteria. RESULTS: The proportions of patients classified as high tumor burden were varied by different criteria. Among the 5 criteria, 7-11 criteria have the best performance to discriminate complete response (CR) and overall survival (OS) after TACE. In patients with low, intermediate, and high tumor burden classified by 7-11 criteria, the CR rate was 21, 12, and 2.5%, respectively (p < 0.001), and the median OS was 33.1, 22.3, and 11.9 months, respectively (p < 0.001). By multivariate analysis, 7-11 criteria were significantly associated with CR (intermediate vs. high burden, odds ratio = 4.617, p = 0.002; low vs. high burden, odds ratio = 8.675, p < 0.001) and OS (intermediate vs. high burden, hazard ratio = 0.650, p < 0.001; low vs. high burden, hazard ratio = 0.520, p < 0.001). Seven to 11 criteria also had the lowest corrected Akaike information criteria, highest homogeneity value, and highest area under the receiver operating characteristic curve in predicting 1-, 2-, and 3-year mortality among all criteria. CONCLUSION: Conventional definitions of tumor burden were not optimal for patients with intermediate HCC. The new 7-11 criteria had the best discriminative power in predicting radiologic response and survival in patients with intermediate-stage HCC undergoing TACE.
Authors: Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero Journal: Hepatology Date: 2018-01 Impact factor: 17.425
Authors: Beom Kyung Kim; Seung Up Kim; Kyung Ah Kim; Yong Eun Chung; Myeong-Jin Kim; Mi-Suk Park; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Man Deuk Kim; Sung Il Park; Jong Yoon Won; Do Yun Lee; Kwang-Hyub Han Journal: J Hepatol Date: 2015-01-29 Impact factor: 25.083
Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Vincenzo Mazzaferro; Josep M Llovet; Rosalba Miceli; Sherrie Bhoori; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sasan Roayaie; Myron E Schwartz; Gian Luca Grazi; René Adam; Peter Neuhaus; Mauro Salizzoni; Jordi Bruix; Alejandro Forner; Luciano De Carlis; Umberto Cillo; Andrew K Burroughs; Roberto Troisi; Massimo Rossi; Giorgio E Gerunda; Jan Lerut; Jacques Belghiti; Ilka Boin; Jean Gugenheim; Fedja Rochling; Bart Van Hoek; Pietro Majno Journal: Lancet Oncol Date: 2008-12-04 Impact factor: 41.316
Authors: Guohong Han; Sarah Berhane; Hidenori Toyoda; Dominik Bettinger; Omar Elshaarawy; Anthony W H Chan; Martha Kirstein; Cristina Mosconi; Florian Hucke; Daniel Palmer; David J Pinato; Rohini Sharma; Diego Ottaviani; Jeong W Jang; Tim A Labeur; Otto M van Delden; Mario Pirisi; Nick Stern; Bruno Sangro; Tim Meyer; Waleed Fateen; Marta García-Fiñana; Asmaa Gomaa; Imam Waked; Eman Rewisha; Guru P Aithal; Simon Travis; Masatoshi Kudo; Alessandro Cucchetti; Markus Peck-Radosavljevic; R B Takkenberg; Stephen L Chan; Arndt Vogel; Philip J Johnson Journal: Hepatology Date: 2020-05-27 Impact factor: 17.425
Authors: Lukas Müller; Felix Hahn; Timo Alexander Auer; Uli Fehrenbach; Bernhard Gebauer; Johannes Haubold; Sebastian Zensen; Moon-Sung Kim; Michel Eisenblätter; Thierno D Diallo; Dominik Bettinger; Verena Steinle; De-Hua Chang; David Zopfs; Daniel Pinto Dos Santos; Roman Kloeckner Journal: Front Oncol Date: 2022-02-23 Impact factor: 6.244